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SUMMARY oxidative stress and insulin resistance (Anderson et al., 2009;Oxidative stress causes mitochondrial dysfunction
and metabolic complications through unknown
mechanisms. Cardiolipin (CL) is a key mitochondrial
phospholipid required for oxidative phosphorylation.
Oxidative damage to CL from pathological remodel-
ing is implicated in the etiology of mitochondrial
dysfunction commonly associated with diabetes,
obesity, and other metabolic diseases. Here, we
show that ALCAT1, a lyso-CL acyltransferase upre-
gulated by oxidative stress and diet-induced obesity
(DIO), catalyzes the synthesis of CL species that are
highly sensitive to oxidative damage, leading tomito-
chondrial dysfunction, ROS production, and insulin
resistance. These metabolic disorders were reminis-
cent of those observed in type 2 diabetes and were
reversed by rosiglitazone treatment. Consequently,
ALCAT1 deficiency prevented the onset of DIO and
significantly improved mitochondrial complex I
activity, lipid oxidation, and insulin signaling in
ALCAT1/mice. Collectively, these findings identify
a key role of ALCAT1 in regulating CL remodeling,
mitochondrial dysfunction, and susceptibility to DIO.
INTRODUCTION
Diabetes and obesity are associated with oxidative stress
and mitochondrial dysfunction, which are implicated in the
etiology of metabolic complications (Anderson et al., 2009;
Bonnard et al., 2008; Houstis et al., 2006). A particularly destruc-
tive aspect of oxidative stress is the productionof reactive oxygen
species (ROS), which have been demonstrated to cause insulin
resistance under different settings (Houstis et al., 2006; Meigs
et al., 2007), impair glucose uptake in insulin-sensitive tissues
(Tirosh et al., 1999), and inhibit insulin-stimulated Akt signaling
(Houstis et al., 2006). Employment of mitochondria-targeted anti-
oxidants has also identified mitochondria as a major source of154 Cell Metabolism 12, 154–165, August 4, 2010 ª2010 Elsevier IncHoustis et al., 2006), which is corroborated by transgenic overex-
pression of antioxidant enzyme targeted to the mitochondria
(Schriner, et al., 2005). Additionally, ROS are highly damaging to
biological molecules such as proteins, nucleic acids, and lipids,
like cardiolipin (CL). Indeed,ROShavebeen shown tocausemito-
chondrial dysfunction by impairing electron transport complex I
and III activity through oxidative damage of CL, a process also
known as CL peroxidation (Paradies et al., 2004).
CL is a polyglycerophospholipid exclusively localized in the
mitochondria,where it regulatesmitochondrial functionandoxida-
tive stress in species from yeast to mammals (Chen et al., 2008;
Chicco and Sparagna, 2007). This role is mediated by the acyl
composition of the side chains of CL, which is dominated by lino-
leic acid in insulin-sensitive tissues (Schlame et al., 2000). This
unique acyl composition is not derived from de novo synthesis of
CL, but rather from a remodeling process that involves phospho-
lipasesandacyltransferase-transacylases (Caoet al., 2004; Taylor
and Hatch, 2009; Xu et al., 2003). Additionally, CL remodeling is
believed to replacedamagedacyl chainsundernormal conditions.
However, this remodeling process is also capable of generating
CL species that are highly sensitive to oxidative damage by ROS
under pathological conditions, further exacerbating CL peroxida-
tion and oxidative stress. CL is highly sensitive to damage of its
double bonds by oxidative stress due to its rich content in linoleic
acid and its location near the site of ROS production in the inner
mitochondrial membrane. Consequently, CL has been shown to
be the only phospholipid in mitochondria that undergoes early
oxidation during apoptosis (Kagan et al., 2005). Therefore, patho-
logical CL remodeling has been implicated in the etiology of mito-
chondrial dysfunction associated with a host of pathophysiolog-
ical conditions, including diabetes, obesity, cardiovascular
diseases, and aging, all of which are characterized by increased
oxidative stress, CL deficiency, and enrichment of docosahexae-
noic acid (DHA) content inCL (Han et al., 2007; Sparagna and Les-
nefsky, 2009). However, little is known about themolecular mech-
anisms governing the pathological remodeling of CL and its
relevance to mitochondrial dysfunction in metabolic diseases.
ALCAT1 is the first lyso-CL acyltransferase identified that
catalyzes the reacylation of lyso-CL to CL, a key step in CL re-
modeling (Cao et al., 2004). In comparison to an isoform of the.
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B Figure 1. ALCAT1 Is Localized at the Mitochon-
dria-Associated Membrane, where It Catalyzes
Remodeling of CL that Leads to Mitochondrial
Dysfunction
(A and B) COS-7 cells overexpressing the FLAG-tagged
ALCAT1 protein were fractionated into mitochondria
(Mito), mitochondria-associatedmembrane (MAM), micro-
somes (micro), and cytosolic fractions. Monolyso-CL acyl-
transferase activity was analyzed from each fraction by
TLC analysis and quantified (B). ALCAT1 and calnexin
(an ER marker) levels in each fraction were analyzed by
western blot analysis (bottom panels).
(C andD) Lipidomic analysis of totalCLand theC16-18acyl
content in CL (C) or the long-chain polyunsaturated acyl
content in CL (D) from C2C12 cells stably overexpressing
ALCAT1 (filled bar) or an empty vector (open bar) by nega-
tive-ion electrospray ionization mass spectrometry.
(E–G) The C2C12 cells stably overexpressing ALCAT1 or
vector were also analyzed for mitochondrial membrane
potentials by flow cytometry (E), oxygen consumption rate
(OCR) by oxygraph (F), and proton leakage as measured
bychanges inOCRafter sequential treatmentwitholigomy-
cin and rotenone (G), whichwas profiled by Seahorse XF24
analyzer and expressed in percentage of basal line.
(H) Upregulation of glycolytic activity by ALCAT1
overexpression inC2C12cells asevidencedbyhigheracid-
ification rate of the culture medium measured by the XF24
analyzers. n = 3, *p < 0.05, **p < 0.01.
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Regulation of Mitochondrial Dysfunction by ALCAT1enzyme recently identified from liver, ALCAT1 lacks preference
for linoleic acid as substrate, suggesting a possible role in the
pathological remodeling of CL (Cao et al., 2004; Taylor and
Hatch, 2009). This is corroborated by recent reports that
ALCAT1 expression is upregulated inmammalian cells exhibitingCell Metabolism 12,tetralinoleoyl-CL deficiency and in heart and
liver of mice suffering from oxidative stress
induced by hyperthyroidism (Cao et al., 2009;
Van et al., 2007). The present investigation
sought to advance our understanding of a regu-
latory role of ALCAT1 in pathological remodeling
of CL and in mitochondrial dysfunction associ-
ated with diet-induced obesity (DIO). These
studies implicate ALCAT1 as a major regulator
of abnormal remodeling of CL in DIO, leading
to oxidative stress, mitochondrial dysfunction,
and insulin resistance.
RESULTS
ALCAT1 Catalyzes Remodeling of CL
with Abnormal Acyl Composition,
Leading to Mitochondrial Dysfunction
The recombinant ALCAT1 protein was previ-
ously shown to be localized in the endoplasmic
reticulum (ER) by immunohistochemical anal-
ysis (Cao et al., 2004). This localization seemed
to contradict with the exclusive localization
of CL in mitochondria. To resolve this issue,
we carried out subcellular fractionation analysis
of the recombinant ALCAT1 protein overex-
pressed in COS-7 cells and analyzed its lyso-CL acyltransferase activity in each of the subcellular fractions.
The results showed that ALCAT1 protein was predominantly
localized in the mitochondria-associated membrane (MAM), as
confirmed by western blot analysis of FLAG-tagged ALCAT1
protein (Figure 1A, lower panel) and by enzyme activity assay154–165, August 4, 2010 ª2010 Elsevier Inc. 155
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Regulation of Mitochondrial Dysfunction by ALCAT1(Figure 1A, upper panel, and quantified in Figure 1B). MAM is
a membrane bridge between the ER and mitochondria and
a major site for phospholipid synthesis and traffic. A significant
portion of the ALCAT1 protein was also detected from the
mitochondrial fraction where CL is synthesized. The results are
supported by a recent report on DGAT2, which was initially
identified as an ER-associated acyltransferase but has recently
been relocalized in the MAM (Stone et al., 2009).
To identify a role of ALCAT1 in regulating CL remodeling and
mitochondrial activity, we generated several C2C12 cell lines
stably transfected with ALCAT1 cDNA expression vector or an
empty vector. C2C12 is a mouse myoblast cell line commonly
used for metabolic research. Using the stable cell lines as
a cell-based model, we first analyzed the effect of ALCAT1 over-
expression on changes in the acyl profile of CL and other phos-
pholipids, including phosphatidylinositol (PI) and phosphatidyl-
glycerol (PG) by mass spectrometric analysis. ALCAT1
overexpression in C2C12 cells caused a 40% reduction in total
CL levels (Figure 1C, 2.74 versus 4.56 nM/mg protein, ALCAT1
versus vector) by selectively decreasing the content of
C16-C18 fatty acids in CL, including linoleic acid, the dominant
acyl form of CL in metabolically active tissues. In contrast, the
level of CL species that contain long-chain polyunsaturated fatty
acid (PUFA) was either unchanged or significantly increased
(Figure 1D). In particular, the level of CL species that contain
DHA (C22:6n3) increased by more than 300%. These changes
in CL acyl profile are similar to those observed in the etiology of
various pathological conditions, including diabetes, obesity,
heart failure, hyperthyroidism, and aging (Gredilla et al., 2001;
Han et al., 2007; Sparagna and Lesnefsky, 2009). In comparison,
there were no significant changes in either acyl composition or
total levels of PI and PG in C2C12 cells overexpressing ALCAT1
relative to the vector control (Figure S1).
Increased DHA content in CL has been shown to stimulate
mitochondrial membrane potential, proton leakage, and ROS
production in cultured cells (Ng et al., 2005; Watkins et al.,
1998). Consistent with increased DHA content in CL, ALCAT1
overexpression caused mitochondrial dysfunction in C2C12
cells by significantly increasing mitochondrial membrane poten-
tial (Figure 1E), oxygen consumption rate (OCR) (Figure 1F), and
proton leakage, as evidenced by significantly higher OCR in
ALCAT1-expressing C2C12 cells in response to treatment of
oligomycin, a mitochondrial ATP synthase inhibitor (Figure 1F).
The effect of ALCAT1 overexpression on mitochondrial leakage
was further confirmed by a Seahorse XF24 analyzer. As shown
by the OCR profile in Figure 1G, C2C12 cells overexpressing
ALCAT1 exhibited a significantly higher OCR than empty-vector
control cells when treated with oligomycin, which was exacer-
bated by treatment with rotenone, a mitochondrial complex I
inhibitor. As a compensatory response to the increased levels
of uncoupling respiration and ROS production, ALCAT1 overex-
pression significantly increased glycolytic activity in C2C12 cells,
as evidenced by significantly higher acidification rate of the
culture medium analyzed by the XF24 analyzer (Figure 1H).
ALCAT1 Causes Oxidative Stress in C2C12 Cells
and Is Upregulated by ROS, DIO, and Type 2 Diabetes
ROS are mainly produced when electrons leak from the
mitochondrial electron transport chain (Kokoszka et al., 2001).156 Cell Metabolism 12, 154–165, August 4, 2010 ª2010 Elsevier IncConsistent with increased proton leakage, overexpression of
ALCAT1 in C2C12 cells significantly increased the intracellular
level of ROS (Figure 2A), which was further exacerbated after
treatment with H2O2. Furthermore, treatment with H2O2 resulted
in significant depletion of mtDNA in C2C12 cells overexpressing
ALCAT1 relative to the vector control cells (Figure 2B).
To provide further evidence for a causative role of ALCAT1 in
oxidative stress, we analyzed the expression of genes involved
in ROS production and oxidative response by real-time RT-PCR
analysis. As shown by Figures 2C and 2D, ALCAT1 overexpres-
sion significantly increased expression of genes that cause
oxidative stress, such as NAD(P)H quinone oxidoreductase-1
(Nqo1) andNADPH oxidase-4 (Nox4), and decreased expression
of genes encoding antioxidative enzymes, including glutathione
peroxidases (Gpx), peroxiredoxins (Prdx), thioredoxin reduc-
tases (Txnrd), and superoxide dismutases (Sod) in C2C12 cells.
The Nqo1 enzyme is essential for oxidative stress in mice and
humans (Voynow et al., 2009), whereas Nox4 is an NAD(P)H
oxidase homolog that stimulates the production of ROS in
insulin-sensitive tissues (Mahadev et al., 2004). The expression
of Nox4 was upregulated more than 29-fold by ALCAT1 overex-
pression in C2C12 cells (Figure 2D). Furthermore, the mRNA
expression of UCP3 was also elevated more than 3-fold, which
is consistent with the increased state 4 respiration caused by
ALCAT1 overexpression (Figure 1G).
To provide direct evidence that links ALCAT1 expression to
oxidative stress, we next analyzed ALCAT1 mRNA expression
in isolated primary cardiomyocytes from C56BL/6 mice in
response to oxidative stress. As shown in Figure 2E, ALCAT1
mRNA expression was significantly upregulated in isolated
cardiomyocytes in culture by tert-butylhydroperoxide (T-Bu),
an oxidant that causes mitochondrial dysfunction, and by H2O2
treatment. The results suggest a causative role of ALCAT1 in
mitochondrial dysfunction in response to oxidative stress in
metabolic diseases, which was supported by upregulation of
ALCAT1 mRNA expression in liver, heart, and skeletal muscle
in response to the onset of DIO in C56BL/6 mice (Figure 2F,
quantified in Figure 2G). Likewise, both ALCAT1 mRNA
expression and enzyme activity were upregulated by the onset
of type 2 diabetes in db/db mice (Figure S2).
ALCAT1/ Mice Are Protected from DIO and Insulin
Resistance
To investigate a regulatory role of ALCAT1 in regulating CL
remodeling and mitochondrial dysfunction associated with
metabolic diseases, we have generated mice with targeted
deletion of the ALCAT1 gene (Figure S3). ALCAT1/ mice
were born with predicted Mendelian ratios without any obvious
phenotypic abnormality when fed a standard mouse chow for
12 weeks. After feeding a high-fat diet containing 60% calories
from animal fat for 8 consecutive weeks, the weight gain in
male ALCAT1/ mice was significantly lower than male wild-
type mice (Figure 3A). Female mice were unaffected (data not
shown). The body weight differences were due to decreased
fat mass in ALCAT1/ mice as measured by 1H-NMR (Fig-
ure 3B). The total body fat content was 8.7% higher in wild-
type mice relative to the ALCAT1/ mice.
We next analyzed changes in glucose homeostasis and insulin
sensitivity in the ALCAT1/mice relative to the wild-type sibling.
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Figure 2. ALCAT1 Causes Oxidative Stress in
C2C12 Cells and Is Upregulated by ROS and by DIO
(A–D) The C2C12 cells stably overexpressing ALCAT1 or
vector used in Figure 1 were analyzed for intracellular level
of ROS before (control) and after treatment with H2O2 (A);
mtDNA copy number in response to H2O2 treatment (B);
the expression of genes encoding antioxidant enzymes,
including peroxiredoxin (Prdx), peroxiredoxin-6-related
sequence (Prdx6-rs1), glutathione peroxidases (Gpx),
superoxide dismutases (Sod), glutathione reductase (Gsr),
nucleoredoxin (Nxn), sulfiredoxin-1 homolog (Srxn1), and
thioredoxin reductase (Txnrd) (C); and expression of genes
encoding oxidant enzymes, including NADPH oxidase-4
(Nox4), dual oxidase-1 (Duox1), NAD(P)H quinone oxidore-
ductase-1 (Nqo1), and uncoupling protein-3 (Ucp3) by
using an oxidative stress pathway real-time PCR microar-
ray kit (D).
(E) ALCAT1 mRNA expression was upregulated in isolated
mouse cardiomyocytes in response to treatment with tert-
butylhydroperoxide (T-Bu), an oxidant, and H2O2, as
measured by RT-PCR analysis using b-actin as an internal
control.
(F and G) ALCAT1 mRNA expression was analyzed in liver,
heart, and skeletal muscle of ALCAT1/ mice (KO) and
the wild-type control (WT) mice fed a normal diet (ND) or
high-fat diet (HFD) by RT-PCR analysis using b-actin as
internal control (F) and quantified (G). SEM, *p < 0.05,
**p < 0.01, compared to vector controls. n = 3.
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Regulation of Mitochondrial Dysfunction by ALCAT1controls. After an overnight fast, blood glucose levels were indis-
tinguishable between the ALCAT1/ and the wild-type controls.
However, blood glucose concentrations were significantly lower
in the ALCAT1/mice thanwild-type during a glucose tolerance
test (Figure 3C). The improvement in glucose tolerance in
ALCAT1/ is most likely caused by enhancement in insulin
sensitivity, as evidenced by the results of the insulin tolerance
tests (Figure 3D). In comparison to wild-type mice, the
ALCAT1/ mice were more sensitive to hypoglycemia induced
by insulin injection (Figure 3D), which is supported by lowerCell Metabolism 12,serum insulin level (Table S2). Since both
genders of the heterozygous ALCAT1 knockout
mice and the female ALCAT1/ mice were not
significantly different from thewild-type controls
in weight gain and insulin/glucose tolerance
(data not shown), subsequent studies were
carried out only in male mice.
Consistent with the finding of reduced fat
content, brown adipose tissue (BAT), and white
adipose tissue (WAT), the ALCAT1/ mice
exhibited smaller fat droplets compared to
those from the wild-type mice when tissue
sections were examined with H&E staining (Fig-
ure 3E). ALCAT1 deficiency caused dramatic
changes of genes involved in energy homeo-
stasis in WAT, including uncoupling protein-2
and -3 (UCP2, UCP3), hormone-sensitive lipase
(HSL), and peroxisome proliferator-activated
receptor g (PPARg), but not carnitine palmitoyl-
transferase I (CPT1). Upregulated mRNA
expression of UCP3, HSL, and PPARg in WATwas consistent with improved insulin sensitivity and higher
energy expenditure in ALCAT1/ mice.
Hyperphagia, Hyperactivity,
and Hypermetabolism in ALCAT1/ Mice
To determine the mechanisms accounting for the resistance to
DIO in ALCAT1/ mice, water intake, physical activity, and
energy expenditure were analyzed over 72 hr in mice housed
in cages equipped with a comprehensive lab animal monitoring
system (CLAMS). As shown by Figure 4A, the lean phenotype154–165, August 4, 2010 ª2010 Elsevier Inc. 157
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Figure 3. ALCAT1/ Mice Are Protected from the
Onset of DIO and Its Related Insulin Resistance
(A–D) Male ALCAT1/ mice and the wild-type control,
8 weeks old, were fed a diet with 60% fat for 8 consecutive
weeks and were analyzed for weight gain (A), body
composition (B), glucose tolerance test (C), and insulin
tolerance test (D). n = 8–10.
(E–H) ALCAT1 deficiency decreased the size of lipid
droplets in brown adipose tissue (BAT) (E) and in white
adipose tissue (WAT) (G) of ALCAT1/ mice as analyzed
by H&E staining. Also shown is analysis of expression of
genes involved in energy metabolism in BAT (F) and in
WAT (H), including uncoupling proteins (UCP), hormone-
sensitive lipase (HSL), peroxisome proliferator-activated
receptor g (PPARg), and carnitine palmitoyltransferase I
(CPT1) by RT-PCR. n = 5–10, *p < 0.05, **p < 0.01.
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Regulation of Mitochondrial Dysfunction by ALCAT1of ALCAT1/ was not secondary to reduced food intake. Actu-
ally, ALCAT1/mice consumed 62%more food and 73%more
water (Figure 4A), respectively, per kg of body weight than wild-
type controls during the 24 hr period. The ALCAT1/mice were
also hyperactive, as evidenced by enhanced physical activity
relative to the wild-type mice (Figure 4B). Consequently, the
energy expenditure rate was significantly higher in ALCAT1/
mice (Figure 4C) due to higher metabolic rate, as evidenced by
the increased OCR (Figure 4D, quantified in Figure 4E). Respira-
tory exchange ratio (RER) during the 24 hr period was signifi-
cantly elevated in the ALCAT1/ mice (Figure 4F, quantified in
Figure 4G), suggesting that the null mice burned more carbohy-
drate as a fuel.158 Cell Metabolism 12, 154–165, August 4, 2010 ª2010 Elsevier Inc.ALCAT1 Deficiency Improves Insulin
Signaling in ALCAT1/ Mice
To gain further insight into the molecular mech-
anisms underlying the improved insulin sensi-
tivity in ALCAT1/, we next analyzed the effect
of ALCAT1 on insulin signaling in C2C12 cell
lines, isolated adipocytes from ALCAT1/
mice, and various tissues of ALCAT1/ and
wild-type mice. As shown in Figure 5A, overex-
pression of ALCAT1 in C2C12 cells significantly
decreased insulin-stimulated Akt phosphoryla-
tion. Conversely, isolated adipocytes in cul-
ture from the ALCAT1/ mice exhibited a sig-
nificant increase in Akt phosphorylation in
response to stimulation by insulin (Figure 5B).
The negative effect of ALCAT1 on insulin
signaling was further corroborated from the
analysis of whole-body insulin sensitivity in
response to acute insulin treatment. As shown
in Figures 5C–5E, insulin-stimulated Akt phos-
phorylation was significantly enhanced in
liver, adipose tissue, and skeletal muscle of
ALCAT1/ mice relative to that from the wild-
type controls. The expression of Akt protein
was also significantly upregulated in liver of the
ALCAT1/ mice (Figure 5C). Consistent with
improved insulin sensitivity, ALCAT1 deficiency
suppressed the phosphorylation of AMPK atThr172, a major activation site. Furthermore, the expression of
AMPK protein was upregulated in skeletal muscle of the
ALCAT1/ mice (Figure 5D), without any effect on JNK expres-
sion or phosphorylation.ALCAT1 Deficiency Suppresses ATP Production Rate,
Analogous to the Effects of an Insulin Sensitizer
Enhanced ATP production rate is associated with severe
insulin resistance in American Indians, whereas insulin stimula-
tion of ATP production is impaired in type 2 diabetic patients
and their insulin-resistant offspring (Asmann et al., 2006;
Petersen et al., 2005). Consistent with a causative role of
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Figure 4. ALCAT1/ Mice Exhibit Hyper-
phagia, Hyperactivity, and Hypermetabo-
lism
(A–G) Male ALCAT1/ mice (/) and the
controls (+/+) from Figure 3 were analyzed for
food intake and water intake (A), physical activity
(B), energy expenditure (C), oxygen consumption
rate (D, quantified in E), and respiratory exchange
ratio (RER) (F, quantified in G) by TSE systems.
n = 6–8, *p < 0.05, **p < 0.01.
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COS-7 or C2C12 cells increased ATP production rate by 50%
in isolated mitochondria when compared to vector control
(Figures 6A and 6B). Conversely, targeted inactivation of endog-
enous ALCAT1 mRNA expression in C2C12 cells by RNA inter-
ference (shRNA) significantly decreased the ATP production
rate (Figure 6B). ALCAT1 overexpression also impaired the stim-
ulating effect of insulin on ATP production rate, as observed in
diabetic patients. As shown in Figure 6C, ATP production rate
was stimulated by insulin in a dose-dependent manner in con-
trol C2C12 cells overexpressing an empty plasmid vector.
In contrast, ATP production rate was blunted in C2C12 cells
overexpressing the ALCAT1 cDNA.
To understand how ATP production was regulated by obesity
and type 2 diabetes, we next analyzed the effect of hypergly-
cemia and an antidiabetic drug on ATP production rate in iso-
lated mitochondria from the liver of db/db mice, a mouse model
of obesity and type 2 diabetes. As shown by Figure 6E, the rate of
ATP production by liver lysates was not different between the
db/db mice and the nondiabetic control mice. In contrast, ATPCell Metabolism 12, 154–1production rate was significantly higher
in isolated mitochondria from liver of
db/dbmice relative to nondiabetic control
mice (Figure 6F). However, this defect
was completely normalized by 4 weeks
of treatment of the db/db mice with rosi-
glitazone, an insulin sensitizer, suggesting
that enhanced ATP production rate is
a major defect in diabetes. In further
support of a role of ALCAT1 in linking
mitochondrial dysfunction to insulin resis-
tance, ATP production rates were signifi-
cantly lower in isolated mitochondria
from liver and heart of ALCAT1/ mice
that exhibit improved insulin sensitivity
(Figure 6D).
Enhanced Mitochondrial Complex I
Activity and Fatty Acid Oxidation
Rate in ALCAT1/ Mice
Oxidative stress impairs mitochondrial
complex I activity through CL peroxida-
tion (Paradies et al., 2002). We next
analyzed the effect of ALCAT1 overex-
pression and deficiency on mitochondrial
complex I activity and oxygen consump-
tion in response to different substrates.In further support of a causative role of ALCAT1 in mitochondrial
dysfunction, ALCAT1 overexpression significantly impaired
mitochondrial complex I and citrate synthase activity (Figures
7A and 7B), which was reversed by ALCAT1 deficiency in
ALCAT/ mice (Figures 7C and 7D). Furthermore, ALCAT1
deficiency also improved mitochondrial respiratory coupling,
as evidenced by significantly lower OCR in isolatedmitochondria
from ALCAT1/ mice in response to treatment with oligomycin
(Figure S4). Mitochondrial fatty acid overload and impaired fatty
acid oxidation is a contributing factor to insulin resistance in
rodents and humans (Bandyopadhyay et al., 2006; Koves
et al., 2008). Consistent with improved hepatic insulin sensitivity
in ALCAT1/ mice as shown by Figure 5C, isolated liver mito-
chondria from the ALCAT1/ mice oxidized palmitoylcarnitine
faster than mitochondria from the control mice on a high-fat
diet (Figure 7F). The use of palmitoylcarnitine bypasses regula-
tion by CPT1, allowing direct assessment of mitochondrial
respiratory function. Conversely, fatty acid oxidation rates
were significantly decreased by the ALCAT1 overexpression in
C2C12 cells (Figure 7E).65, August 4, 2010 ª2010 Elsevier Inc. 159
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Figure 5. Effects of ALCAT1 Overexpres-
sion and Deficiency on Insulin Signaling in
C2C12 Cell Lines and in Mouse Tissues
(A) The C2C12 cell lines used in Figure 2 were
treated with the indicated concentrations of insulin
and analyzed for Akt phosphorylation (Thr308 and
Ser473) and total Akt level on the same blot by
western blot analysis.
(B) ALCAT1 deficiency improved insulin signaling
in isolated adipocytes in culture from ALCAT1/
mice (KO) versus wild-type mice (WT).
(C–E) Mice from Figure 4 were treated with insulin
(1 unit/kg, i.p.) and were analyzed for Akt phos-
phorylation in the liver, skeletal muscle, and
adipose tissues by western blot analysis. The
same blots were also analyzed for phosphorylation
of AMPK and JNK and total protein level of each
kinase (t-Akt, t-AMPK, and t-JNK) using b-actin
as an internal control for protein loading.
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Regulation of Mitochondrial Dysfunction by ALCAT1Obesity increases the level of lipid peroxidation by oxidative
stress (Olusi, 2002). Since ALCAT1 overexpression stimulated
ROS production in C2C12 cells, we questioned whether ALCAT1
deficiency would suppress oxidative stress in ALCAT1/ mice.
This was done by analyzing changes in the level of thiobarbituric
acid reactive substances (TBARS), an indicator of lipid peroxida-
tion from oxidative stress. Consistent with increased ROS in
C2C12 cells overexpressing ALCAT1 (Figure 2C), the TBARS
level was significantly lower in liver of ALCAT1/ mice relative
to the wild-typemice (Figure 7G). In contrast, ALCAT1 deficiency
had no significant effect on oxidative stress in fat and skeletal
muscles.Upregulated Expression of Mitochondrial Trifunctional
Protein, Cardiac Tetralinoleoyl-CL, and Hepatic PG in
ALCAT1/ Mice
To identify molecular mechanisms accounting for a causative
role of ALCAT1 in pathological remodeling of CL, we next
analyzed the effect of ALCAT1 on the expression of trifunctional
protein (TFP), which was recently reported to encode MLCL AT,
a mitochondrial isoform of ALCAT1. As shown in Figure 7H, TFP
expression was completely suppressed by ALCAT1 overexpres-160 Cell Metabolism 12, 154–165, August 4, 2010 ª2010 Elsevier Inc.sion in H9c2 cell lines. Conversely, TFP
expression was significantly upregulated
by ALCAT1 deficiency in liver of
ALCAT1/ mice (Figure 7I). Consistent
with a previously reported role of MLCL
AT in catalyzing beneficial CL remodeling
(Taylor and Hatch, 2003), cardiac CL from
ALCAT1/ mice demonstrated a signifi-
cant increase in linoleic acid content
(6.27 versus 4.35 nmol/mg protein,
p < 0.001, ALCAT1/ versus control)
compared to heart from wild-type mice
(Figure S5A). Additionally, total CL
concentrations were significantly
elevated in the heart of ALCAT/ mice
relative to the wild-type controls (19.08versus15.05 nmol/mg protein, p < 0.05, ALCAT1/ versus
control). Finally, ALCAT1 deficiency also increased the total
concentration of hepatic PG by more than 400% (4.74 versus
0.99 nmol/mg protein, p < 0.001, ALCAT1/ versus control)
without a significant impact on the total CL level in liver of
ALCAT1/ mice (Figure S5B).DISCUSSION
Diabetes and obesity are characterized by CL deficiency and
profound remodeling of CL’s acyl composition through unknown
mechanisms (Han et al., 2007; Sparagna et al., 2007; Watkins
et al., 2002). The current studies identified a key role of ALCAT1
in catalyzing the synthesis of CL species that are highly suscep-
tible to oxidative damage. Accordingly, ALCAT1 overexpression
in C2C12 cells led to CL deficiency and alterations of acyl
composition of CL reminiscent of those observed in diabetes
without major effects on other phospholipids. Conversely,
ALCAT1 deficiency significantly increased the levels of tetralino-
leoyl-CL in heart and PG in the liver of ALCAT1/mice. PG is an
immediate biosynthetic precursor of CL and can substitute for
some essential functions of CL (Jiang et al., 2000). Both CL
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Figure 6. Regulation of Mitochondrial ATP
Production Rate by ALCAT1 and Type 2
Diabetes
(A) Isolated mitochondria from COS-7 cells over-
expressing ALCAT1 were analyzed for ATP
production rate. The expression level of the
FLAG-tagged ALCAT1 was verified by western
blot analysis (bottom panel).
(B) ATP production rate was analyzed from stable
C2C12 cell lines used in Figure 1 and C2C12 cells
with ALCAT1 deficiency mediated by shRNA
(shRNA). The mRNA level of ALCAT1 was verified
by RT-PCR analysis (bottom panel).
(C) ATP production rate was analyzed inmitochon-
dria isolated from the stable C2C12 cell lines used
in (B) and pretreated with the indicated doses of
insulin.
(D) ATP production rate was analyzed in isolated
mitochondria from liver and heart of the
ALCAT1/ mice.
(E) ATP production rates were unchanged in liver
protein lysate of db/db mice.
(F) ATP production rate was analyzed in
mitochondria isolated from livers of 10-week-old
db/db diabetic mice, the nondiabetic controls
(WT), and the db/db diabetic mice pretreated
with 0.375 mg/day of rosiglitazone for 4 consecu-
tive weeks (db + rosi). n = 5, *p < 0.05, **p < 0.01.
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(Han et al., 2005). The results are further corroborated by a major
role of ALCAT1 as a negative regulator of TFP, a newly identified
ALCAT1 isoform also known as MLCL AT (Taylor and Hatch,
2009). In contrast to ALCAT1, MLCL AT catalyzes CL remodeling
by increasing the content of linoleic acid, leading to an increase
of the ‘‘good’’ CL (Cao et al., 2004; Taylor and Hatch, 2003).
Thereby, TFP expression was significantly downregulated by
ALCAT1 overexpression in C2C12 cells and upregulated by
ALCAT1 deficiency in the liver of ALCAT1/ mice.
One of the major unresolved questions in metabolism is how
oxidative stress contributes to the onset of mitochondrial
dysfunction in metabolic diseases. The results from the current
studies suggest CL remodeling by ALCAT1 as a missing linkCell Metabolism 12, 154–1between oxidative stress and mitochon-
drial dysfunction, which is supported by
multiple lines of evidence. First, ALCAT1
overexpression leads to CL deficiency
and enrichment of DHA content, which
is known to increase mitochondrial
membrane potential, oxidative stress,
and lipid peroxidation (Hong et al., 2002;
Watkins et al., 1998). Second, ALCAT1
causes proton leakage, as evidenced by
upregulation of UCP3 expression and
state 4 respiration in C2C12 cells. The
mitochondrial defects are similar to those
observed in rodent models of diabetes,
obesity, and hyperthyroidism (Boudina
et al., 2007; Short et al., 2007). Third,
ALCAT1 overexpression significantlyincreases ROS production in C2C12 cells, which is exacerbated
in response to H2O2 treatment. The increased ROS production is
explained by upregulation of genes encoding oxidant enzymes
and downregulation of those encoding antioxidant enzymes.
For example, the expression of Nox4, an NAD(P)H oxidase
homolog, was increased more than 29-fold. Nox4 stimulates
the production of ROS in insulin-sensitive tissues (Mahadev
et al., 2004), which is a major source of ROS in diabetic animals
(Block et al., 2009). Upregulated Nox4 expression could also
contribute to the higher OCR observed in C2C12 cells overex-
pressing ALCAT1. Fourth, ALCAT1 mRNA expression is upregu-
lated in primary mouse cardiomyocytes and in insulin-sensitive
tissues in responses to oxidative stress (Figure 2E), DIO
(Figure 2F), and hyperthyroidism (Cao et al., 2009), which65, August 4, 2010 ª2010 Elsevier Inc. 161
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Figure 7. EnhancedMitochondrial Complex
I Activity, Fatty Acid Oxidation, and Trifunc-
tional Protein Expression in Liver of
ALCAT1/ Mice
(A and B) Mitochondrial complex I activity (A) and
citrate synthase activity (B) were analyzed in
C2C12 cells as used in Figure 1.
(C and D) Mitochondrial complex I activity (C) and
citrate synthase activity (D) were analyzed in iso-
lated liver mitochondria from ALCAT1/ (/)
and wild-type control (+/+) mice.
(E and F) Palmitoylcarnitine oxidation rate was
analyzed from C2C12 cells used in Figure 1 (E)
and from isolated mitochondria from the liver of
the ALCAT1/ mice (/) and the wild-type
controls (+/+) (F).
(G) Lipid peroxidation levels, as indicated by the
level of malonaldehyde (MDA), were analyzed in
tissue lysate from liver, skeletal muscle, and fat
of the ALCAT1/ mice and the controls by
a TBARS kit. n = 4.
(H and I) Western blot analysis of TFP from C2C12
cells used in Figure 1 (H) or from liver lysates of
wild-type (WT) and the ALCAT1/ (KO) mice on
high-fat diet (HFD) (I), using anti-b-actin antibodies
(internal control).
(J) A schematic diagram depicts a causative role
of ALCAT1 in mitochondrial dysfunction and
insulin resistance. n = 6–8, *p < 0.05, **p < 0.01.
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cantly reduces the level of lipid peroxidation in liver of the
ALCAT1/ mice on HFD.
Mitochondrial dysfunction has been proposed to be a unifying
cause of diabetes and obesity (Lowell and Shulman, 2005), yet
the underlying molecular mechanisms remain elusive (Turner
and Heilbronn, 2008). Several early studies suggested that mito-
chondrial oxidative function is compromised in diabetic and
prediabetic humans (Bandyopadhyay et al., 2006; Mootha
et al., 2004) and their offspring (Petersen et al., 2004). However,
several recent reports suggest mitochondrial hyperactivity and
overload as major defects associated with severe insulin resis-
tance in Asian Indian immigrants in the United States (Nair
et al., 2008) and in animal models of diabetes and obesity (Koves
et al., 2008; Pospisilik et al., 2007). Our work on CL remodeling
by ALCAT1 suggests an alternative molecular mechanism by
which mitochondrial hyperactivity causes insulin resistance.
Accordingly, the ATP production rate was stimulated by ALCAT1
overexpression and insulin resistance in C2C12 cells and was162 Cell Metabolism 12, 154–165, August 4, 2010 ª2010 Elsevier Inc.downregulated in ALCAT1/ mice that
exhibit enhanced insulin sensitivity and
signaling. These observations are further
corroborated by enhanced mitochondrial
ATP production rate in db/dbmice, which
is normalized by treatment with rosiglita-
zone. Rosiglitazone reduces oxidative
stress (Bagi et al., 2004; Quintanilla
et al., 2008) and improves mitochondrial
function by increasing levels of total CL,
the linoleic acid content in CL (Pan
et al., 2006; Watkins et al., 2002), and
the expression of enzymes involved in fatty acid metabolism,
including TFP (Wilson-Fritch et al., 2003, 2004). TFP is a trifunc-
tional enzyme localized in the inner mitochondrial membrane,
where it catalyzes three out of the four steps in the b-oxidation
cycle. TFP deficiency in humans and rodents causes severe fatty
acid oxidation disorder (den Boer et al., 2003), fatty liver, insulin
resistance, and oxidative stress (Ibdah et al., 2005; Tonin et al.,
2010). Consequently, fatty acid oxidation was impaired by TFP
deficiency in C2C12 cells overexpressing ALCAT1 and was
enhanced in isolated hepatic mitochondria by upregulated TFP
expression in ALCAT1/ mice. In further support of a causative
role of ALCAT1 in insulin resistance, insulin-stimulated Akt phos-
phorylation and ATP production rate were blunted in C2C12 cells
overexpressing ALCAT1, analogous to those observed in dia-
betic humans (Asmann et al., 2006; Petersen et al., 2005), which
are reversed by ALCAT1 deficiency.
Importantly, the present findings carry additional implications
for future studies on other metabolic diseases, since patholog-
ical CL remodeling has been identified as a common defect in
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et al., 2001; Han et al., 2007; Pan et al., 2006; Sparagna and
Lesnefsky, 2009). Our results prompt speculation that CL
remodeling by ALCAT1 may be a common denominator in
oxidative stress and mitochondrial dysfunction associated with
metabolic diseases and aging (Figure 7J). Accordingly, upregu-
lation of ALCAT1 in response to ROS causes CL peroxidation,
which leads to oxidative stress and mitochondrial dysfunction,
further exacerbating ROS production, insulin resistance, and
other metabolic complications. Consequently, inhibition of
ALCAT1 by chemical reagents may provide a potential treatment
for obesity and other metabolic diseases.
EXPERIMENTAL PROCEDURES
Shotgun Lipidomics Analysis of CL Species
The lipidomics analysis was carried out using methods previously described
(Han et al., 2007). Briefly, total lipids from C2C12 cells and animal tissues
were analyzed by triple-quadruple mass spectrometer (MS) (Thermo Electron
TSQ Quantum Ultra) controlled by Xcalibur system software. All the MS
spectra and tandemMS spectra were automatically acquired by a customized
sequence subroutine operated under Xcalibur software.
Mitochondrial Membrane Potential and Intracellular ROS
Mitochondrial membrane potential (DJ) and intracellular ROS generation in
C2C12 cells were investigated using TMRM (T-668, Invitrogen; Carlsbad,
CA) or 2’,7’-dichlordehydrofluorescein-diacetate (DCFH-DA) (Molecular
Probes; Eugene, OR) at a final concentration of 200 nM or 5 mM, respectively.
Cells were incubated with dye in culture medium for 30 min at 37C and then
resuspended in 0.5 ml PBS and submitted to flow cytometric analysis using
FACSCalibur Flow Cytometer (Becton Dickinson; San Jose, CA).
Oxygen Consumption in Intact Cells
OCRs were measured in intact cells using a SOM-2 PO2 Clark oxygen elec-
trode. C2C12 cells, 3 3 106 total, were suspended in 1.4 ml DMEM culture
medium and transferred into the chamber, which was maintained at 37C.
After equilibration and stirring, basal respiration was measured as the average
oxygen consumption over 5min, followed by sequential injection of oligomycin
(2.5 mg/ml final concentration) and p-trifluoromethoxy carbonyl cyanide phenyl
hydrazone (FCCP, 2 mM final concentration), respectively.
Mitochondrial Isolation and ATP Production Rate Assay
Cells were harvested in 1 ml homogenization buffer (20 mM HEPES, 140 mM
KCl, 5 mM MgCl2-6H2O, 1 mM EDTA [pH 7.4]) and homogenized for 3 min on
ice. The homogenate was then centrifuged at 600 3 g, 4C, for 5 min, and the
supernatant was centrifuged for 10 min at 10,0003 g, 4C, to pellet mitochon-
dria. Then mitochondrial ATP production rate was measured using the
ENLITEN ATP Assay System (Promega; Madison, WI) with 1420 Multilabel
Counter (PerkinElmer; Fremont, CA).
Mitochondrial Complex I Activity Assay
The complex I (NADH-CoQ reductase) activity was measured in mitochondria
as well as in cell homogenate generated by sonication of cell pellet in 50 mM
phosphate buffer (pH 7.2). The assay mixture contained 2 mM NaCN, 2 mg/ml
antimycin A, and 0.1 mM decylubiquinone. The mitochondrial sample or cell
sample (75 mg total protein) was added to 1 ml of the assay mixture, and the
reaction was started by the addition of 200 mM NADH. The reaction was
measured by following the decrease in absorbance of NADH at 340 nm with
a spectrophotometer. The activity was calculated by an extinction coefficient
of 6.22 mM1cm1 for NADH. Citrate synthase activity was used as a mito-
chondrial enzymatic marker. Mitochondria or cell homogenates (50 mg total
protein) were added to a buffer with 100 mM Tris-HCl, 1 mM 5,50-dithiobis-
2-nitrobenzoic acid, 3 mM acetyl-CoA (pH 8), and 0.2% Triton X-100 (vol/
vol). The reaction was started by the addition of 1 mM oxaloacetate, and the
initial rate was measured following the decrease of absorbance at 420 nm
wavelength.CelFatty Acid Oxidation Assay
Fatty acid oxidation rates were measured in liver mitochondria and C2C12
cells using sealed vials in a volume of 0.4 ml in a medium (25 mM sucrose,
75 mM Tris-HCl, 10 mM KH2PO4, 5 mMMgCl2, and 1 mM EDTA [pH 7.4]) sup-
plemented with 5 mM ATP, 1 mM NAD+, 0.1 mM CoA, 0.5 mM L-carnitine,
0.5 mM L-malate, and 25 mM cytochrome c. C2C12 cells were cultured in
a 25 cm2 flask to reach 80%–90% confluency. After washing three times
with cold PBS, the cells were cultured in 0.4 ml low-glucose DMEM supple-
mented with 2% BSA. The assay was started by injecting 0.1 ml of
600 mmol/l [14C]palmitoylcarnitine, and incubated at 37C for 15 min for iso-
lated mitochondria or 60 min for cell lysate. The reaction as stopped by the
addition of 0.2ml 20%perchloric acid. After 90min of shaking at room temper-
ature, the production level of [14]CO2 was analyzed by liquid scintillation
counter (Beckman Instruments; Brea, CA).
Body Composition, Energy Expenditure, Activity, and Food Intake
Body fat and lean body mass were measured using an LF90 TD-NMR (Bruker
Optics; Billerica, MA). Measurements of food and water intake, energy
expenditure, RER, and physical activity were performed using metabolic
cages (TSE Systems; Bad Homburg, Germany) for 3 consecutive days.
Constant airflow (0.4 l/min) was drawn through the chamber and monitored
by a mass-sensitive flow meter. The concentrations of oxygen and carbon
dioxide were monitored at the inlet and outlet of the sealed chambers to calcu-
late oxygen consumption and RER. Each chamber was measured for 1 min at
15 min intervals. Physical activity was monitored by infrared technology
(OPT-M3, Columbus Instruments; Columbus, OH), as the count of 3D beam
breaking (X total, Y ambulatory, and Z) was measured.
Statistical Analysis
Statistical comparisons were done using two-tailed nonpaired t tests to
determine the difference between the two C2C12 cell lines and between
ALCAT1/ and wild-type mice. Analysis of covariance (ANCOVA) was also
used to assess differences between ALCAT1/ and wild-type mice in meta-
bolic parameters relative to total body weight and lean weight. Data are
expressed as means ±SEM.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and two tables and can be found with this article online at
doi:10.1016/j.cmet.2010.07.003.
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